How much does lapatinib cost? What is the reimbursement rate for medical insurance?

Lapatinib (Lapatinib) is an oral anti-cancer drug that belongs to a category of targeted therapy drugs. It was first approved by the U.S. Food and Drug Administration (FDA) in 2007 for the treatment of breast cancer and is usually used to treat a specific type of breast cancer, HER2 positive breast cancer.

Lapatinib is already on the market in China, but it has not yet been included in medical insurance. Patients can purchase it domestically at a price of around 5,000 to 6,000 yuan. Please consult the local hospital pharmacy for specific prices. There are original lapatinib drugs and generic drugs abroad. The original drug is cheaper than the original drug in Türkiye, which costs more than 2,000 yuan. Generic drugs include Indian generic drugs and Bangladeshi generic drugs, and the price is around a few hundred yuan. The ingredients of domestic original drugs, foreign original drugs and generic drugs are basically the same.

The mechanism of action of lapatinib is to reduce the growth and division of cancer cells by inhibiting the activation of HER2 and EGFR (epidermal growth factor receptor) receptors. HER2 and EGFR are proteins that are abnormally active in some breast cancer cells and promote tumor growth and spread. The special thing about lapatinib is that it is a dual-targeted drug that acts on both receptors at the same time, so it can inhibit tumor proliferation more effectively.

Lapatinib is often used as part of a breast cancer treatment regimen, especially in patients who have received poor response to other treatments. It can be used alone or in combination with other chemotherapy drugs or other targeted drugs, and the specific treatment plan will be based on the patient's specific situation.

However, lapatinib is not without side effects. Some common side effects include diarrhea, skin rash, nausea, vomiting, and sometimes more serious heart problems. Therefore, before using lapatinib, doctors will conduct a comprehensive evaluation of the patient to ensure that the patient is suitable for treatment with this drug.